Harbor Advisory Corp MA Decreases Stock Position in AbbVie Inc. $ABBV

Harbor Advisory Corp MA reduced its position in AbbVie Inc. (NYSE:ABBV) by 11.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 19,477 shares of the company’s stock after selling 2,400 shares during the period. AbbVie makes up approximately 1.3% of Harbor Advisory Corp MA’s holdings, making the stock its 26th largest holding. Harbor Advisory Corp MA’s holdings in AbbVie were worth $4,450,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the company. Goldenstone Wealth Management LLC purchased a new stake in AbbVie in the fourth quarter worth $377,000. FourThought Financial Partners LLC increased its position in AbbVie by 1.3% in the fourth quarter. FourThought Financial Partners LLC now owns 17,240 shares of the company’s stock worth $3,939,000 after buying an additional 215 shares during the last quarter. Global Retirement Partners LLC increased its position in AbbVie by 13.9% in the fourth quarter. Global Retirement Partners LLC now owns 110,681 shares of the company’s stock worth $25,289,000 after buying an additional 13,482 shares during the last quarter. Great Diamond Partners LLC increased its position in AbbVie by 1.2% in the fourth quarter. Great Diamond Partners LLC now owns 9,935 shares of the company’s stock worth $2,270,000 after buying an additional 118 shares during the last quarter. Finally, Mach 1 Financial Group LLC increased its position in AbbVie by 180.1% in the fourth quarter. Mach 1 Financial Group LLC now owns 9,034 shares of the company’s stock worth $2,064,000 after buying an additional 5,809 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $214.86 on Friday. The firm has a market capitalization of $379.60 billion, a price-to-earnings ratio of 105.84, a P/E/G ratio of 0.73 and a beta of 0.32. AbbVie Inc. has a 52-week low of $180.25 and a 52-week high of $244.81. The stock has a fifty day moving average of $208.95 and a 200 day moving average of $219.71.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the company earned $2.46 earnings per share. Equities analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics unit, received a positive CHMP opinion in Europe for Boey® (trenibotulinumtoxinE) to treat moderate to severe glabellar lines, a step that could expand AbbVie’s aesthetics franchise if formal approval follows. Article: Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
• Positive Sentiment: AbbVie said it will present new oncology data at ASCO 2026, highlighting momentum across its next-generation cancer pipeline in solid tumors and blood cancers, which supports longer-term growth expectations. Article: AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
• Positive Sentiment: Piper Sandler reiterated an Overweight rating and raised its price target on AbbVie, citing strength in the company’s inflammatory bowel disease pipeline and Skyrizi-related progress. Article: AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength
• Neutral Sentiment: Analyst-style articles on undervaluation may offer some support to investor sentiment, but they do not appear to be direct company-specific catalysts for ABBV. Article: 3 Stocks That May Be Undervalued By The Market In May 2026
• Negative Sentiment: AbbVie also faces some headline risk after reports that its patent plea for the hepatitis C drug Mavyret was rejected in India, which could weigh on sentiment around parts of its older portfolio. Article: AbbVie’s Patent Plea for Hepatitis C Therapy Mavyret Rejected in India

Insider Activity

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on ABBV. Canaccord Genuity Group raised their target price on AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $253.43.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.